Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Bacthera.

    Client Virtual Booth

    BACTHERA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Bacthera
    Denmark Flag
    Country
    Country
    Denmark
    Address
    Address
    Kogle Allé 6 2970 Hørsholm
    Telephone
    Telephone
    +(45) 70 22 60 60
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.bacthera.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/bacthera/?originalSubdomain=ch
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Microba Commences Phase I Clinical Trial for IBD Therapeutic

    Details:

    MAP 315 is a live biotherapeutic product (LBP) consisting of lyophilised bacteria in an enteric coated capsule which is orally administered and being developed as an investigational product for the treatment of IBD and ulcerative colitis (UC).


    Lead Product(s): MAP 315

    Therapeutic Area: Gastroenterology Product Name: MAP 315

    Highest Development Status: Phase IProduct Type: Large molecule

    Recipient: Microba Life Sciences

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 27, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection

    Details:

    The collaboration with Bacthera will expand the commercial production capacities of SER-109 and provide supply support. SER-109, Seres’ lead product candidate for recurrent Clostridioides difficile infection (rCDI).


    Lead Product(s): Firmicute Species Bacterial Spores

    Therapeutic Area: Infections and Infectious Diseases Product Name: SER-109

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Seres Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration November 10, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    fermion-oy-2024-05-13

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search